Physician profile
Patrick Wayne Collins
NPI 1629043476
$12,245.28
in general payments reported to CMS, 2019-2025
46 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $1,471 · 2021: $1,880 · 2022: $2,187 · 2023: $1,884 · 2024: $1,738 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,200 · Education: $86.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,199.95 |
| Education | $86.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,668.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,595.18 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $906.80 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Glaxosmithkline, LLC. | $890.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $878.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $836.02 | 2019-2025 | |
| Amgen INC. | $607.97 | 2019-2022 | |
| Lilly USA, LLC | $400.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.79 | 2019-2025 | Xifaxan |
| Allergan, INC. | $342.45 | 2019-2020 | |
| Amarin Pharma, INC. | $331.30 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $294.46 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.93 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $255.88 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $249.99 | 2019-2025 | Eliquis, Camzyos |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.